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Multinodular goiter (MNG) is the most common disorder of the thyroid gland. 
It is highly endemic in iodine-deficient areas; MNG can be seen in almost all 
individuals with severe iodine-deficient areas. It starts as a diffuse enlargement 
of the thyroid gland and ends in a nodular enlarged thyroid. Though MNG can 
be sporadic, there is a strong correlation between occurrence of MNG and iodine 
deficiency. The characteristic feature of MNG is its functional and structural 
heterogeneity. The MNG usually presents as neck swelling; rarely it may produce 
pressure symptoms, i.e., dyspnea, hoarseness of voice, and dysphagia. It can also 
present with symptoms of hyperthyroidism particularly in long-standing goiter. 
Imaging particularly ultrasound is very useful to define characteristic of MNG and 
surrounding structure. The incidence of malignancy in MNG is 4–14%, and risk 
factors are family history of thyroid carcinoma, history of neck radiation, prior 
surgery, and presence of cervical lymphadenopathies. Management of MNG can be 
done by drugs, surgery, and radioiodine (I-131) depending on results of diagnostic 
evaluation and associated complications.
Keywords: hyperthyroidism, iodine, goiter, MNG, multinodular goiter, 
thyrotoxicosis
1. Introduction
Goiter is the enlargement of the thyroid gland which can be due to a variety of 
conditions. Nodular goiter is one of the most common endocrine disorders affecting 
the thyroid gland. It is endemic to certain populations and regions especially those 
with iodine deficiency. It also tends to occur with a higher frequency in women 
and in the fourth to fifth decades of life [1]. The prevalence of goiter is variable 
worldwide and is correlated with iodine intake of regional populations. In approxi-
mately 3600 B.C., Chinese medical writings were the first to show a decrease in size 
of goiter after ingestion of seaweed and burnt sea sponge, and they continued to 
remain as effective remedies for goiter worldwide as was documented in the writ-
ings of Hippocrates, Galen, Roger, and Arnold [2].
After initiation of iodine prophylaxis programs in over 2100 school girls in 
the United States in 1917 by David Marine and colleagues, iodized salt was intro-
duced in the United States in 1922 for prevention of endemic goiter. Later in 1930 
iodized salt became widely available in the United States [3]. The salt iodization is 
a good approach for decreasing iodine deficiency in population, as it is a universal 
foodstuff, inexpensive, and easily available and intake is relatively consistent [4]. 
Approximately 120 countries, including the UK, Canada, Brazil, China, India, 
Thailand, and Singapore, have adopted mandatory iodization of all food-grade salt 
[5]. Currently the WHO recommends daily intake of 150 mcg iodine for adults, 
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250 mcg for pregnant and lactating women, and 90 mcg for children <2 years of 
age that can be easily obtained by iodized salt, processed food, and milk products 
[6]. Prevalence of goiter still remains 4–7% in the United States even after iodine 
supplementation [7].
Goiter can be classified as solitary or multiple, diffuse or nodular, and toxic 
or nontoxic on an anatomical and functional basis. The nontoxic goiter is due to 
abnormalities of iodine supplies or metabolism without any abnormal thyroid func-
tion. In children goiter tends to be smaller and diffuse, whereas in older people they 
are usually large and nodular.
2. Etiology and pathophysiology
Thyroid hormones affect the function of virtually all organ systems of the body; 
these are critical determinants of brain and somatic development in infants and of 
metabolic activity in adults. The thyroid gland is regulated to a large extent by the 
delicate balance between the hypothalamus, pituitary, and thyroid. Thyrotropin-
releasing hormones (TRH) are secreted by the hypothalamus which stimulates 
the secretion of the thyroid-stimulating hormone (TSH), by the pituitary gland. 
TSH is a major regulator of the thyroid gland which after binding to its receptor on 
plasma membrane stimulates each and all steps of thyroid hormone synthesis and 
secretion.
Goiter is an etiologically and pathogenetically complex disease. The specific role 
of TSH in its pathogenesis has not been unraveled. It has been variously defined and 
characterized by the increased volume of the thyroid gland with the formation of 
multiple nodules. Although a number of definitions exist, the most accepted is the 
thyroid gland weighing over 20–25 g or a volume of over 19 ml in females and 25 ml 
in males [8].
Grossly, MNG reveals a heterogeneous array of solid/cystic and mixed nodules. 
Cystic nodules are typically defined as a cystic component >50%. Typically, patho-
genesis of MNG thyroid can be attributed to three main processes: diffuse follicular 
hyperplasia, focal nodular proliferation, and eventual acquisition of functional 
autonomy. Development of goiter especially in conditions of iodine deficiency or 
Hashimoto’s disease seems to be TSH driven. However, in addition to TSH, several 
other growth factors, both TSH dependent and independent, have been known to 
play a role in the pathogenesis of MNG by influencing thyroid follicular cell growth. 
Chronic stimulation of follicular cells primarily due to TSH leads to follicular 
hyperplasia, which usually then enters a resting phase leading to the formation of 
colloid goiter [9]. This long-standing diffuse goiter may develop into MNG with the 
potential of autonomy in certain nodules. The role of genetic factors especially in 
nontoxic MNG is not clear, but some role has been suggested by twin studies, family 
history, female preponderance, etc. [10]. Certain mutations like those affecting 
the activation of camp cascade (e.g., TSH-r mutations) which stimulates growth 
and function mutation in genes encoding thyroglobulin (Tg), thyroid peroxidase 
(TPO), dual oxidase 2 (THOX2), the sodium-iodide symporter gene (SLC5A5), 
Pendred syndrome gene (SLC26A4), the TSH receptor gene (TSHR gene), the 
iodotyrosine deiodinase (DEHAL 1), and the thyroid oxidase 2 gene (THOX2) 
have been found to be responsible in certain cases for the formation of nodules in 
a patient with MNG [10]. Familial MNGs have been found to be strongly associ-
ated with mutations in the miRNA processing gene DICER1 [11]. Environmental 
factors have also been incriminated in causation of MNG possibly by aggravating 
the expression of heterogeneity causing the thyroid to grow and perhaps leading 
to its autonomy. Naturally occurring goitrogens are thought to work by different 
3Multinodular Goiter
DOI: http://dx.doi.org/10.5772/intechopen.90325
mechanisms, leading to impaired thyroid hormone synthesis or thyroid growth 
(Table 1). For example, iodine-rich substances like seaweed and cruciferous and 
cassava may impair iodine uptake [12]. In addition to this protein energy malnutri-
tion and deficiency of other nutrients like iron and selenium, vitamin a may also be 
associated with thyroid enlargement if present with iodine-deficient state. The non-
functioning nodules in nontoxic MNG may over time evolve into larger autonomous 
nodules, leading first to a smoldering subclinical hyperthyroid state which may then 
progress to overt hyperthyroidism [13]. The Marine Lenhart disease is functioning 
thyroid nodules associated with Graves’ disease.
3. Types of goiter
3.1 Toxic MNG
Toxic MNG is a result of activating somatic mutation of the TSH receptor gene 
that leads to diffuse hyperplasia of thyroid follicular cells independent of TSH 
regulation [14–16]. MNG with thyrotoxicosis is also known as Plummer’s disease. 
Toxic MNG presented with clinical features similar to other causes of thyrotoxi-
cosis except ophthalmopathy. Incidence of thyrotoxicosis in MNG is related to the 
duration of the presence of MNG. So it’s more common in elderly people who are 
harboring MNG for a long time. Hormone profile in toxic MNG is seen with sup-
pressed TSH along with normal or elevated thyroid hormones.
3.2 Graves’ disease
Graves’ disease is an autoimmune disorder caused by anti-TSH receptor anti-
body. These antibodies interact with TSH receptor and cause increased thyroid 
hormone synthesis and secretion [17]. Many risk factors have been found in causa-
tion of Graves’ disease including high iodine intake and stress [18, 19]. Several 
drugs have also been implicated in etiology of Graves’ disease including lithium, 
Goitrogens Agent Action
Millet, soy Flavonoids Impairs thyroperoxidase activity





Inhibits iodine thyroidal uptake




Glucosinolates Impairs iodine thyroidal uptake
Seaweed (kelp) Iodine excess Inhibits release of thyroidal hormones
Malnutrition Vitamin A deficiency
Iron deficiency
Increases TSH stimulation, Reduces heme-
dependent thyroperoxidase thyroidal 
activity
Selenium Selenium deficiency Accumulates peroxides and causes 
deiodinase deficiency; impairs thyroid 
hormone synthesis
Adapted and modified from Medeiros-Neto and Knobel [48].
Table 1. 
Natural goitrogens associated with goiter prevalence.
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interferon α, and alemtuzumab [20–22]. Other autoimmune manifestations associ-
ated with Graves’ disease are pretibial myxedema and ophthalmopathy. Graves’ 
disease is the most common cause of thyrotoxicosis [23]. It is more common in 
females and usually presents before 30 years of age. Graves’ disease presents with 
classical symptoms of thyrotoxicosis, i.e., irritability, sleeplessness, palpitations, 
excessive sweating, heat intolerance, and weight loss.
3.3 Hashitoxicosis
Hashitoxicosis, a term coined from Hashimoto’s disease and thyrotoxicosis, is 
a rare condition seen in patients with autoimmune thyroid disease. Hashitoxicosis 
presents initially with clinical features of thyrotoxicosis and is associated with high 
radioiodine uptake similar to Graves’ disease [24]. Later on it leads to development 
of hypothyroidism which is caused by lymphocytic infiltration and autoimmune 
destruction of thyroid gland similar to Hashimoto’s thyroiditis. Anti-TSH receptor 
antibodies are found in nearly 23% of patients with hashitoxicosis [25].
3.4 Subacute (DeQuervain’s) thyroiditis
It is a nonsuppurative thyroiditis caused by viral infection or as a result of 
post-viral illness. In twin study, some link of genetic association was also found 
[26]. Subacute thyroiditis is characterized by neck pain and tenderness. Initially 
disease presents with fever, fatigue, and myalgia along with hyperthyroidism that 
is followed by euthyroidism and then hypothyroidism, and lastly euthyroidism 
is achieved. A less or absent uptake is seen by radionuclide uptake study. Color 
Doppler study reveals low blood flow in the hyperthyroid phase which normalizes 
once euthyroidism is achieved. On laboratory study TSH remains suppressed, and 
free T4 and free T3 are raised during the hyperthyroid phase.
3.5 Riedel’s thyroiditis
Riedel’s thyroiditis is a rare condition of unknown etiology occurring in 
middle-aged women. In this chronic thyroiditis, thyroid follicles are replaced by 
fibrous tissue. Association with other autoimmune fibrosclerotic disease, i.e., 
retroperitoneal fibrosis and sclerosing cholangitis, is also found. Initially patients 
present with goiter with normal thyroid function but later on become hypothyroid. 
The diagnosis can be made with FNAC, but sometimes biopsy may be required for 
confirmation.
4. Clinical evaluation of MNG
MNG is usually detected incidentally during routine examination for evaluation 
of some other disease. Sometimes the patient seeks help for obvious neck swelling 
and cosmetic disfigurement of the neck. As MNG becomes palpable once the size 
is more than 1 centimeter, so large MNG mainly presents with neck swelling. Once 
MNG is detected, a complete history and physical examination focusing on the 
thyroid gland and adjacent cervical lymph nodes should be performed. Through 
history including history of childhood head and neck radiation therapy, total body 
radiation for bone marrow transplantation, exposure to ionizing radiation from 
fallout in childhood or adolescence, familial thyroid carcinoma, or thyroid cancer 
syndrome should be sought [27, 28]. Patients with long-standing MNG are more 
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likely to have clinical features of thyrotoxicosis, and they usually present with sub-
clinical or clinical hyperthyroidism during evaluation. The MNG may present with 
compressive features, i.e., dyspnea and dysphagia. Respiratory symptoms develop 
due to tracheal compression. Hoarseness of voice may result from compression of 
recurrent laryngeal nerve. Very rarely MNG may present with vocal cord palsy, but 
it is usually seen in malignancy. Retrosternal MNG with thoracic inlet compression 
can be diagnosed with Pemberton’s maneuver, in which raising arm overhead causes 
flushing and shortness of breath due to compression of neck veins. Information 
regarding family members, any significant drug use, and radiation exposure should 
also be enquired. Thyroid examination should be done in sitting position, and dur-
ing palpation information regarding thyroid shape, nodularity, tenderness, and 
fixity to the surrounding should be sought. Fixation to trachea, esophagus, and sur-
rounding structure raises the possibility of malignancy. Enlarged painful and 
tender thyroid can be due to subacute thyroiditis or thyroid abscess. Neck mass with 
enlarged cervical lymph node again raises suspicion of carcinoma and warrants 
further evaluation.
5. Laboratory investigation
American Thyroid Association (ATA) recommends serum TSH as the initial lab-
oratory test in evaluation of MNG. If serum TSH is abnormal, then serum FT4 and 
serum FT3 are recommended to know the thyroid’s functioning status. Antithyroid 
peroxidase (anti TPO) antibody and thyroglobulin (Tg) are other laboratory tests to 
know about thyroid autoimmunity and Tg gene mutation in patients with MNG. If 
TSH is high, the risk of malignancy is increased, so it warrants further evaluation 
with imaging and FNAC [29–30].
6. Imaging study
6.1 Thyroid ultrasonography
Thyroid ultrasound is the most widely accepted imaging modality to know the 
characteristic of MNG. Ultrasound can give information regarding the number of 
nodules and the size and location of nodules within the thyroid. It also provides 
information regarding the presence or absence of any suspicious cervical lymph 
nodes in the neck. Thyroid sonography can also describe features including com-
position (solid, cystic proportion, or spongiform), echogenicity, margins, presence 
and type of calcifications, shape if taller than wide, and vascularity which helps 
in making decision of FNAC (Figure 1). Thyroid ultrasound is commonly used in 
ultrasound guided FNAC for greater yield in diagnosis.
6.2 Radionuclide scan
Although radionuclide imaging of thyroid gland has been done for a long time, 
resolution of this modality for thyroid nodule is far behind the ultrasonography 
[31]. So radionuclide imaging is not having much role in anatomic description 
of MNG. However radionuclide imaging is very useful in describing physiology 
of thyroid nodules. If TSH is subnormal, then ATA recommends a radionuclide 
thyroid scan to know whether nodules are hyperfunctioning (“hot,” i.e., tracer 
uptake is greater than the surrounding normal thyroid), isofunctioning (“warm,” 
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i.e., tracer uptake is equal to the surrounding thyroid), or nonfunctioning (“cold,” 
i.e., has uptake less than the surrounding thyroid tissue) [32]. Since hyperfunction-
ing nodules rarely harbor malignancy, so cytologic evaluation is not required in 
hyperfunctioning nodules. Scan is also useful in distinguishing Graves’ disease from 
(toxic MNG) Plummer’s disease.
6.3 CT/MRI
CT/MRI is generally not recommended in evaluation of MNG. These modalities 
of imaging do not have any advantage over ultrasonography in description of intra-
thyroidal structure. These imaging modalities are useful only when malignancy is 
suspected or goiter is retrosternal in which MRI is more precise than CT. CT/MRI 
provides more information about the surrounding tissue in relation to the thyroid, 
i.e., trachea, esophagus, and neck vessels. So these imaging modalities are used 
when features of tracheal compression/deviation, dysphagia, vocal cord paralysis, 
and weight loss are present. CT/MRI provides additional anatomical information to 
be helpful preoperatively for planning of surgical excision.
6.4 FNAC
ATA recommends FNAC as the procedure of choice in evaluation of MNG, as 
it is the cost-effective and most accurate method for thyroid nodule evaluation. 
FNAC is very reliable and has a low false-negative (7%) and very low false-positive 
rate near to zero [33]. In one study negative predictive value of case classified as 
benign was 95% [34]. FNAC provides an algorithm for evaluation and management 
of patients with thyroid nodules based on sonographic pattern and FNA cytology. 
ATA recommends FNAC in nodule >1 cm with high or intermediate suspicion of 
malignancy, nodule >1.5 cm with low suspicion of malignancy, and nodule >2 cm 
Figure 1. 
Nodule sonographic patterns and risk of malignancy.
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with very low suspicion of malignancy. FNAC is not recommended for purely cystic 
nodule. To make a satisfactory FNAC, at least six to eight cell clusters are required in 
two slides. ATA recommends FNAC to be reported using diagnostic groups outlined 
in the Bethesda system for reporting thyroid cytopathology (Table 2). Based on 
literature review and expert opinion, the Bethesda system has six diagnostic cat-
egories and also provides an estimation of cancer risk within each category. These 
categories are (i) nondiagnostic/unsatisfactory; (ii) benign; (iii) atypia of undeter-
mined significance/follicular lesion of undetermined significance (AUS/FLUS);  
(iv) follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), a category 
that also encompasses the diagnosis of Hu¨rthle cell neoplasm/suspicious for 
Hürthle cell neoplasm; (v) suspicious for malignancy (susp); and (vi) malignant.
7. Treatment
Treatment of MNG is directed towards existing thyroid disease associated with 
MNG and etiology of the disease [35]. Management of toxic and nontoxic MNG 
is done separately and should be based on the type of MNG. Treatment selection 
is also based on overall health and comorbidities of the patient. Success of treat-
ment depends on the patient selection and type of treatment. Treatment is broadly 
divided in surgical and nonsurgical modalities. Surgery is indicated in large MNG, 
retrosternal extension of MNG, compression of trachea or esophagus, rapid 
growth, suspicion of malignancy, and MNG associated with vocal cord palsy.
7.1 Surgical treatment
Definitive treatment of toxic MNG is done by surgery when goiter size is large. 
Two types of surgical procedures are performed: total thyroidectomy and subtotal 
thyroidectomy. In total thyroidectomy all thyroid tissue is surgically excised, 
whereas in subtotal thyroidectomy small amount of thyroid tissue 1 gm on each 
lobe of thyroid is left. Before doing surgical procedure, patient should be rendered 
euthyroid by antithyroid drugs, beta blockers, and potassium iodide or a combina-
tion of one or more of these. Preoperatively cardiac evaluation is mandatory, and 
patient should be stabilized with appropriate treatment. Surgical procedures are the 
Diagnostic category Estimated/predicted risk of 
malignancy by the Bethesda 
system, %a
Actual risk of malignancy 
in nodules surgically 
excised, % median 
(range)b
Nondiagnostic or unsatisfactory 1–4 20 (9–32)
Benign 0–3 2.5 (1–10)
Atypia of undetermined significance 
or follicular lesion of undetermined 
significance
5–15 14 (6–48)
Follicular neoplasm or suspicious for 
a follicular neoplasm
15–30 25 (14–34)
Suspicious for malignancy 60–75 70 (53–97)
Malignant 97–99 99 (94–100)
As reported in the Bethesda system by Cibas and Ali.
Table 2. 
The Bethesda system for reporting thyroid cytopathology: Diagnostic categories and risk of malignancy.
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same for toxic and nontoxic MNG. In nontoxic MNG preoperative treatment with 
antithyroid drugs, beta blockers, or potassium iodide is not required.
Although most surgeons prefer to do total thyroidectomy, still controversy exists 
regarding the removal of thyroid tissue in between total and subtotal thyroidectomy 
for surgical treatment of MNG. In study temporary or permanent recurrent laryn-
geal nerve palsy, temporary or permanent hypoparathyroidism, hemorrhage, and 
wound complications were not significantly different in total thyroidectomy versus 
subtotal thyroidectomy [36]. In an analysis, goiter recurrence was significantly 
more in subtotal thyroidectomy than total thyroidectomy, but reintervention due 
to goiter was not significantly higher. Incidence of permanent recurrent laryngeal 
nerve palsy and permanent hypoparathyroidism was more in the total thyroidec-
tomy group, but it was statistically nonsignificant [37]. Postoperatively serum TSH 
level should be monitored, many physicians prefer to start thyroid hormone as 
theoretically this may prevent recurrence of goiter, but studies have not shown this 
kind of benefit from thyroid hormone suppressive therapy [38–39].
7.2 Medical treatment
Levothyroxine (LT4) is used as TSH suppression therapy with variable success 
for nontoxic goiter. But suppressive therapy with LT4 is associated with thyrotoxi-
cosis particularly in elderly patients. In this subset of patients, it is associated with 
osteopenia and cardiac arrhythmia and is inversely related to TSH concentration. 
Very rarely thyroid nodules can become functionally autonomous [40–41]. The 
goal is to keep TSH in between 0.1 mIU/L and 0.4 mIU/L. However the suppressive 
therapy is still a matter of debate. A meta-analysis of 11 studies has shown a twofold 
increase of chance in reduction in nodule size with LT4 suppressive therapy with 
proper selection of patient [42]. In another study with 54 patients 12 months after 
starting suppressive therapy, 37.1% of patients with single, solid nodules are found 
to regress more than 50% in nodule volume, and 20.3% of patients had reduction 
in nodule volume more than 20% but less than 49.9%. One-third of subjects with 
MNG had 50% or more regression of the glandular volume, whereas 46.8% were 
considered as nonresponsive. During suppressive therapy with LT4, the mean serum 
Tg level was also decreased significantly in these patients [43]. Because of lifelong 
therapy is required for prevention of goiter recurrence and is associated with risk 
of autonomous functioning of nodules, so in many patients, TSH suppression with 
LT4 is not feasible.
Antithyroid drugs propylthiouracil and thionamides (carbimazole and 
methimazole) are used to restore euthyroidism in toxic MNG. They can be used 
for a long time in patients whom surgery and radioiodine (I-131) treatment are 
contraindicated. But risk of agranulocytosis remains a major concern. In a recent 
study, methimazole was used for 8 years in 53 patients for treatment of toxic MNG 
without any serious adverse effect [44].
7.3 Radioiodine (I-131)
Radioiodine (I-131) is in use for management of thyroid disorder for more 
than 50 years. Radioiodine (I-131) is used particularly for thyrotoxic disorder 
mainly in Graves’ disease. Radioiodine (I-131) also causes a significant reduction 
of thyroid gland volume. Due to its effect on reduction of thyroid gland volume, 
it has been used in management of nontoxic nodular thyroid disease also. In one 
study, 35 patients with nontoxic large MNG were treated with mean 1806 mbq 
(range 800–4000) of I-131. The mean reduction in thyroid volume was 43.18% 
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study 63.4 ± 3.6% reduction in volume was seen with I-131 in rhTSH-treated 
nontoxic MNG patients [46]. Treatment with radioiodine (I-131) also relieves 
symptoms of tracheal and esophagus compression in large MNG. In toxic MNG 
radioiodine (I-131), euthyroid state is restored in addition to decrease of nodule size 
in MNG. Pretreatment with rhTSH increases the uptake of radioiodine (I-131) by 
thyroid tissue in a homogenous manner so that cold areas also take up radioiodine 
(I-131). In a small study, pretreatment with rhTSH is associated with greater reduc-
tion of thyroid volume in radioiodine (I-131)-treated patient [47]. Treatment with 
radioiodine (I-131) is also associated with adverse effects in a few cases, i.e., hypo-
thyroidism, radiation thyroiditis, and autoimmune hyperthyroidism. Although 
long-term studies have not demonstrated carcinogenic effect of radioiodine (I-131), 
still concern regarding thyroid cancer, leukemia, and congenital abnormalities in 
offspring remains in mind.
8. Conclusion
MNG is the most common thyroid disorder, but usually it is asymptomatic. 
When large enough it can cause compression to the trachea, esophagus, and neck 
veins. Other complications of MNG are autonomous functioning nodules, and very 
rarely it may progress to malignancy. Diagnostic evaluation includes clinical evalu-
ation, thyroid function, and imaging study. Additional testing with FNAC may be 
required. Treatment modalities include drugs, surgery, and radioiodine (I-131), 
depending on results of diagnostic evaluation and associated complications.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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